Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26F56XR
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $20,436
Award facts
- Contract value 100% obligated
- $20,436.16 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $20,436.16 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors on December 19, 2025, with completion scheduled for December 22, 2025. This competitively awarded, firm fixed-price delivery order represents a continuation of pharmaceutical supply under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis, eosinophilic esophagitis, and moderate-to-severe asthma, making this order part of the Defense Health Agency's comprehensive pharmaceutical procurement strategy for military healthcare systems. The order is being fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania.
This delivery order derives from AmerisourceBergen's substantial $999.999 billion indefinite delivery contract with DLA Troop Support Medical (SPE2DX) through December 2026, which serves as the primary pharmaceutical supply vehicle for global military healthcare programs. As a major pharmaceutical distributor and critical federal vendor, AmerisourceBergen maintains extensive capability to supply specialty medications, branded and generic drugs, vaccines, and medical supplies across multiple therapeutic areas to military installations and defense health systems worldwide. The non-set-aside status of this award reflects the company's competitive standing within open federal procurement processes for pharmaceutical products and medical supplies.
Quick answers
Who was awarded contract SPE2DR26F56XR?
SPE2DR26F56XR was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on December 19, 2025.
How much is contract SPE2DR26F56XR worth?
The government has obligated $20,436 on SPE2DR26F56XR.
Is contract SPE2DR26F56XR an order under another contract?
Yes. SPE2DR26F56XR is a delivery order under SPE2DR25D2006, an indefinite delivery contract.
Was contract SPE2DR26F56XR competed?
The extent of competition for SPE2DR26F56XR was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award